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Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings,
Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014
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On  July  9,  2014,  Aeras  and  the  Max  Planck  Institute  for Infection  Biology  convened  a workshop  entitled
“Whole  Mycobacteria  Cell  Vaccines  for Tuberculosis”  at the  Max  Planck  Institute  for  Infection  Biology  on
the grounds  of  the  Charité  Hospital  in Berlin,  Germany,  close  to  the  laboratory  where, in  1882,  Robert
Koch  ﬁrst  identiﬁed  Mycobacterium  tuberculosis  (Mtb) as the pathogen  responsible  for  tuberculosis  (TB).
The  purpose  of  the  meeting  was  to discuss  progress  in  the  development  of  TB  vaccines  based  on whole
mycobacteria  cells.  Live  whole  cell TB  vaccines  discussed  at  this  meeting  were  derived  from  Mtb itself,
from  Bacille  Calmette–Guérin  (BCG),  the  only  licensed  vaccine  against  TB,  which  was  genetically  modiﬁed
to  reduce  pathogenicity  and  increase  immunogenicity,  or from  commensal  non-tuberculous  mycobacte-
ria.  Inactivated  whole  cell  TB  and  non-tuberculous  mycobacterial  vaccines,  intended  as  immunotherapy
or  as safer  immunization  alternatives  for HIV+  individuals,  also  were  discussed.  Workshop  participants
agreed  that  TB  vaccine  development  is signiﬁcantly  hampered  by imperfect  animal  models,  unknown
immune  correlates  of  protection  and the  absence  of  a human  challenge  model.  Although  a  more  effective
TB  vaccine  is needed  to replace  or enhance  the  limited  effectiveness  of  BCG  in all  age groups,  members
of  the  workshop  concurred  that  an effective  vaccine  would  have  the  greatest  impact  on  TB control  when
administered  to  adolescents  and  adults,  and  that  use  of  whole  mycobacteria  cells as  TB  vaccine  candi-
dates  merits  greater  support,  particularly  given  the  limited  understanding  of the  speciﬁc  Mtb  antigens
necessary  to  generate  an  immune  response  capable  of  preventing  Mtb infection  and/or  disease.
1. Introduction
Dr. Stefan H.E. Kaufmann, Managing Director, Max  Planck
Institute for Infection Biology and Professor of Immunology and
Microbiology, Charité Clinics, Berlin, Germany
The development of an effective vaccination to prevent the
spread of tuberculosis (TB) represents an important global health
priority. It is estimated that one third of the world’s pop-
ulation is infected with Mycobacterium tuberculosis (Mtb). In
2013, approximately 9 million persons developed active TB, and
approximately 1.5 million died of the disease [1]. In 2014, the
WHO set a goal of reducing incidence of active TB from the
current level of greater than 100 cases per 100,000 persons
Abbreviations: AFB, acid-fast bacteria; BCG, Bacille Calmette–Guérin; CFU,
colony forming units; DAT, diacyltrehalose; DDA, dimethyldioctadecylammonium;
ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot
assay; HIV, human immunodeﬁciency virus; Hly, listeriolysin O; IFN-, Inter-
feron gamma; INH, isoniazid; LAM, lipoarabinomannan; LTBI, latent TB infection;
MDR, multidrug-resistant; MGIA, mycobacterial growth inhibition assay; MPL,
monophosphoryl lipid-A; Mtb, Mycobacterium tuberculosis; NHP, non-human pri-
mate; NKT, natural killer T-cells; PAT, polyacyltrehalose; PDIM, phthiocerol
dipimycocerosate; PPD, puriﬁed protein derivative; SATVI, South African Tubercu-
losis Vaccine Initiative; SL, Sulfolipid; TB, tuberculosis; TNF, tumor necrosis factor;
VPM, Vakzine Projekt Management; WHO, World Health Organization; Zmp, zinc
metalloprotease.
to 10 cases per 100,000 persons by 2035, and reducing mortality by
95% [1]. Models of disease reduction strategies suggest that current
TB control strategies will not be sufﬁcient to reach this goal unless a
vaccine capable of preventing TB infection and/or disease becomes
available [2–4].
Sixteen different TB vaccine candidates are currently in clinical
trials, with more in the preclinical pipeline. Most of these vac-
cine candidates are subunit vaccines, where selected Mtb  antigens
are expressed in recombinant viral vectors or are administered
as protein/adjuvant combinations [5]. Approximately 12 different
antigens are expressed in the subunit vaccines currently in clinical
trials. A major challenge to TB vaccine development, however, is the
lack of an immune correlate of protection against Mtb  infection or
TB disease [6]. Accordingly, there is little certainty about the actual
protective effect that may  be provided by at least some of the anti-
gens currently under investigation in subunit vaccine candidates
[7].
Given these concerns, whole mycobacteria cell vaccines are
receiving a fresh look as an attractive TB vaccine development
strategy [8]. The most familiar whole cell vaccine for TB is Bacille
Calmette–Guérin (BCG). Working in the Institute Pasteur in Lille,
France, Albert Calmette and Camille Guérin passaged a Mycobac-
terium bovis isolate over a period of 16 years, from 1906 to 1921,
eventually developing a strain sufﬁciently attenuated to administer
safely to humans [9,10]. Since its ﬁrst use in 1921, BCG has become
the most widely used vaccine in history, with approximately 4
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billion doses administered worldwide [5]. The full effectiveness of
BCG vaccination, however, has yet to be accurately determined.
There is consensus that BCG administered to infants shortly after
birth reduces the risk of severe childhood TB, particularly TB menin-
gitis and disseminated TB. A meta-analysis of the global effect of
BCG vaccination on childhood tuberculous meningitis and mili-
tary TB estimated that in 2002, about 30,000 cases of tuberculous
meningitis and 11,500 cases of military TB were prevented by the
100.5 million BCG vaccinations given to infants in that year [11].
Accordingly, the WHO  recommends neonatal BCG immunization
in countries endemic for TB [11,12]. BCG also may  provide children
a degree of protection against Mtb  infection for a limited number
of years after vaccination, although observational studies suggest
that this effect is variable and likely is impacted by the latitude in
which the child lives, with children in tropical latitudes exhibiting
less protection from subsequent childhood infection, possibly due
to a higher rate of exposure to other non-tuberculous mycobacteria
[13,14].
Despite its widespread use, BCG vaccination has important lim-
itations. Recent studies in BCG-immunized pediatric populations
estimates total incident childhood cases of all forms of TB in 2011
to be almost 1 million, twice that estimated by WHO, and provides
an initial assessment of multidrug-resistant (MDR) TB cases at over
30,000 [15]. In addition, BCG is not recommended for use in HIV-
infected infants because of the risk of disseminated BCG disease
[16]. Most importantly, the ongoing global epidemic of TB infec-
tion, disease and death among adolescents and adults is occurring
in populations in which infant BCG vaccination is nearly universal.
Accordingly, developing a more effective whole cell vaccine than
BCG represents an important goal of global TB control efforts.
The July 9, 2014 whole mycobacteria cell TB vaccine workshop,
convened in the shadow of the laboratory of Robert Koch, discov-
erer of the Mtb  bacillus more than 130 years previously, speciﬁcally
examined the potential role of whole mycobacterial cells as vac-
cines to prevent infection and/or disease due to Mtb. The workshop
was divided into three sessions: (1) the research and development
status of seven whole cell TB vaccines; (2) development pathways
for whole mycobacteria cell vaccines, focusing on the rationale for
and public health implications of developing replacement BCG vac-
cines for infants and for using whole cell vaccines to prevent Mtb
infection and disease in adolescents and adults; and (3) resource
needs for developing whole cell TB vaccines, with a focus on the
identiﬁcation of standardized assays for vaccine immunogenicity
and efﬁcacy to permit reliable vaccine candidate comparisons. A
summary of the whole mycobacteria cell vaccines for TB discussed
in this workshop can be found in Table 1.
2. Status of ongoing whole mycobacteria cell vaccine
research and development
BCG + ESAT-6 recombinants. Dr. Roland Brosch, Institut Pas-
teur, Unit for Integrated Mycobacterial Pathogenomics, Paris,
France
Dr. Roland Brosch described efforts by his laboratory to improve
the BCG vaccine. Theorizing that BCG may  be lacking some impor-
tant genetic features to provide effective protection against Mtb, Dr.
Brosch proposed that vaccine immunogenicity and efﬁcacy may  be
improved by adding back a gene cluster to BCG that was  lost dur-
ing the BCG passaging and attenuation process. All BCG vaccines
lack the RD1 locus, the region of difference 1 [17,18]. The RD1 locus
encodes at least 11 genes, including the immunodominant T-cell
antigens ESAT-6 (6-kD early secretory antigenic target) and CFP-
10 (10-kD culture ﬁltrate protein), both representing important
mycobacterial antigens secreted by the ESX-1 type VII secretion
system, representing potential Mtb  virulence factors. Restoration
of the entire RD-1 locus to BCG is required for ESAT-6 secretion
and partially restores virulence [18]. When the recombinant BCG,
BCG::ESX-1, was compared to the parental BCG for immunogenic-
ity and protection against an Mtb  challenge [19], it was  shown
to be more virulent in immune deﬁcient mice, more persistent
in immune competent mice, but also more effective in protecting
against disseminated TB in both mice and guinea pigs [18,19].
As a possible explanation for the increased virulence in severe
combined immune deﬁcient (SCID) mice and the improved pro-
tective vaccine efﬁcacy of the recombinant strain, it was found
that ESAT-6 may  disrupt lipid bilayers [20,21], thereby providing
a mechanism for ESX-1 proﬁcient tubercle bacilli to egress from
the macrophage phagosome to the cytoplasm [22,23]. The effect
of ESAT-6 on the fate of macrophage-phagocytized BCG also was
studied with the ﬂuorescent substrate, CCF-4. BCG is unable to
progress from the phagosome to the cytoplasm, while BCG::ESX-
1 moves to the cytoplasm with Mtb  kinetics. Phagosomal rupture
is followed by necrotic cell death of infected macrophages, result-
ing in BCG::ESX-1spread to new host cells. Access to the cytosol
by the recombinant BCG::ESX-1 allows additional immunological
responses and higher amounts of antigen, in part also explaining
the stronger CD8+ T-cell responses observed for Mtb  relative to BCG
[24].
A series of recombinant, ESX-1 proﬁcient BCG constructs were
developed that retain ESX-1 function but reduce the virulence.
Mutation of ESAT-6 leads to less virulent recombinant BCG vac-
cines that express and secrete modiﬁed ESAT-6 antigens which
proved to provide better protection in mouse models and to be
somewhat more protective in a guinea pig model than the parental
BCG Pasteur strain (Bottai and Brosch, unpublished results). The use
of different BCG strains as a template for ESX-1 complementation,
such as BCG Moreau, also is being explored. Finally, attempts also
are being made to use the recombinant BCG::ESX-1 Mar, created
using the ESX-1 system from Mycobacterium marinum, a biosafety
class 2 organism, to complement BCG strains. Preliminary results
for this approach are promising (Groschel and Brosch, unpublished
results). Dr. Brosch concluded his presentation by emphasizing
that the ESX-1 locus encodes genes critical for mycobacterial host
pathogen interaction, and that inclusion of this locus in recombi-
nant BCG vaccines is expected to enhance the immune response to
the vaccine on multiple levels which seem all to be impacted by the
ability of the vaccine to gain access to the host cytosol [25].
VPM1002. Dr. Leander Grode, Vakzine Projekt Management
GmbH, Hannover, Germany. Dr. Umesh Shaligram, Serum Insti-
tute of India Ltd., Pune, India
Dr. Leander Grode and Dr. Umesh Shaligram jointly discussed
progress in scaling up production of the vaccine candidate
VPM1002, and shared the results of Phase 1 and Phase 2 clinical
trials. VPM1002 employs the pore-forming protein listeriolysin O
(Hly) from the facultative anaerobic bacterium Listeria monocy-
togenes, coupled with a urease C gene deletion in a BCG Prague
genetic background, to allow antigen to escape from the phago-
some into the cytoplasm of the infected cell [26]. The BCG bacteria,
however, remain in the phagosome [26]. Acidic pH is optimal
for Hly activity; deletion of the urease C gene prevents BCG
neutralization of the naturally acidic phagosome environment
[27]. A safety feature of this vaccine is the four amino acid PEST
sequence (P, proline; E, glutamic acid; S, serine; T, threonine)
which targets the Hly protein for rapid degradation in the cytosol
[28,29]. Following entry into the cytosol, the Hly protein is rapidly
inactivated, thereby reducing the possibility of adverse events
due to the pore-forming bioactivity of this protein. Antigen access
to the cytosol is presumed to allow for a broader activation of
immune mechanisms and improved vaccine efﬁcacy [30–33].
VPM1002 initially was  created in the laboratory of Dr. Stefan
H.E. Kaufmann [34,35] and was further developed by VPM. In 2013,
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Table  1
Whole mycobacteria cell vaccines for tuberculosis under development.
Vaccine Description Indication Clinical trials Comments
Recombinant BCG BCG, essential virulence genes
(e.g., ESAT-6) restored
BCG replacement None Early preclinical studies to date
VPM1002 BCG, listeriolysin O gene added,
urease C gene deleted
BCG replacement;
disease prevention in
BCG vaccinated adults;
bladder cancer
Phase 1 and 1b completed.
Phase 2 in neonates ongoing
Phase 3 in HIV+/− neonates in
planning
MTBVAC M.  tuberculosis, live, attenuated
via deletions in phoP and
fadD26
BCG replacement Phase 1 in progress Phase 2 in neonates planned
for 2015
DAR-901 Mycobacteria obuense, heat
inactivated, sonicated
Disease prevention in
BCG vaccinated adults,
especially HIV+
Phase 1, 2, 3 studies with
agar-grown SLR-172 precursor
to DAR-901 completed. Phase 1
with reformulated,
broth-grown DAR-901 in
progress.
Phase 3 planned in HIV+/−
adults; Inactivated vaccine,
safe for HIV+
RUTI M.  tuberculosis, fragmented,
Triton cleaned, liposomal
grown under anoxic stress
Immunotherapy to
support and reduce TB
and LTBI chemotherapy
Phase 1 and 2 completed Two Phase 3 trials planned; not
a  live vaccine, safe for HIV+
BCG  zmp1 BCG, zinc metallo-protease 1
deletion (zmp1)
BCG replacement None Late preclinical development
Adjuvanted, non-replicating BCG BCG, panCD, auxotrophic for
pantothenate
Boost after BCG prime
in adolescents, adults
and HIV+
None Potentially more reactogenic
than BCG
the rights to the vaccine were acquired by SII, which has developed
a new large-scale production process for the vaccine. VPM1002 is
being developed primarily as a BCG replacement vaccine for pre-
vention of serious TB disease in infants. It also is being evaluated as
a replacement for BCG immunotherapy of bladder cancer.
Preclinical studies in mice showed that, in contrast to BCG,
VPM1002 reproducibly protected against an aerosol challenge
model to a clinical isolate of Mtb  of the Beijing/W lineage [26].
Safety assessment of bacilli persistence in wild type mice found
that VPM1002 fell below the level of detection 40 days after immu-
nization while BCG was detectable 90 days after immunization, The
ﬁrst Phase 1 clinical trial of VPM1002 was completed in Germany
in 2012 [36]. The study consisted of adult male Caucasian volun-
teers with and without prior exposure to BCG. It was  shown to
be safe and similar in immunogenicity to BCG [36]. A subsequent
Phase 1B trial in South Africa tested VPM1002 in BCG immunized
adults. VPM1002 again was found to be safe and immunogenic as a
boost to pre-existing immunity from a BCG prime [27,36]. A Phase
2, head-to-head comparison of BCG to VPM1002 in HIV-unexposed
neonates recently was completed in South Africa. VPM1002 was at
least as well tolerated as BCG in this trial; immunogenicity results
are pending. A second Phase 2 clinical trial is planned to begin
in January 2015 in South Africa in HIV-exposed and -unexposed
populations of BCG-naïve neonates.
MTBVAC. Dr. Carlos Martín, Department of Microbiology, Fac-
ulty of Medicine, University of Zaragoza, Zaragoza, Spain
Dr. Carlos Martin reported on the development of MTBVAC, the
only live-attenuated Mtb-based vaccine currently in clinical trials
[37]. The rationale behind the development of an attenuated Mtb
vaccine is to immunize with a candidate that manifests as close an
antigenic picture to Mtb  as possible while minimizing the virulence.
The Geneva Consensus on new live mycobacterial vaccines
requires two  non-reverting independent mutations to live, Mtb-
based vaccines to insure the stability of the attenuation, without the
inclusion of antibiotic resistance markers [38,39]. MTBVAC meets
these requirements as it contains deletions in the genes encod-
ing fadD26 and phoP and does not contain an antibiotic resistant
marker. The fadD26 gene product is involved in the synthesis of
the lipid phthiocerol dipimycocerosate (PDIM), a major mycobac-
terial virulence factor. The phoP gene encodes a transcriptional
regulator that controls the expression of two percent of the cod-
ing capacity of Mtb  genome, including gene families involved in
respiration, the hypoxic response, lipid metabolism, stress proteins
and the RD1 region, which includes ESAT-6 [40]. The deletion in
phoP reduces the virulence mainly from abrogation of the ESX-1
secretion system. As a result of this deletion, MTBVAC maintains
the ability to produce ESAT-6 but cannot secrete this, therefore
losing the ability to spread from cell to cell [41]. In addition, the
phoP deletion results in the loss of MTBVAC complex lipids, such
as diacyltrehaloses (DAT), polyacyltrehaloses (PAT) and sulfolipids
(SL), that could interfere with the immune system [40,42]. The
resulting vaccine is an attenuated Mtb  that is transformed from
an immune-evasive to an immune-recognizable bacterium. Pre-
clinical studies in mice demonstrated better protection than BCG
[37,43]. Additionally, MTBVAC performs as well or better than
BCG in non-human primates (NHPs) [44]. MTBVAC efﬁcacy may  be
ascribed to improved antigenicity properties following silencing
of the noncoding RNA Mcr7 and the ensuing increase in secre-
tion of Twin Arginine Translocation (Tat) substrates, such as the
Ag85 proteins, considered as major antigens of Mtb  [42]. Phase
1 clinical trials designed to compare MTBVAC to BCG were ini-
tiated in January 2013 in Switzerland, in healthy adults negative
for PPD, BCG and HIV. The vaccine was safe at all three doses
tested; immunogenicity results are not yet available. In addition
to standard immunogenicity assays, a transcriptomics study will be
performed to better understand the molecular basis of the immune
response to the vaccine. A Phase 1b clinical trial in neonates is
planned for 2015.
DAR-901. Dr. C. Fordham von Reyn, Infectious Disease and
International Health, Geisel School of Medicine, Hanover, New
Hampshire
Dr. Ford von Reyn reported on the development of DAR-901,
a vaccine designed to be safe and effective in both HIV-
infected and -uninfected individuals. DAR-901 is a poly-antigenic,
heat-inactivated, whole cell vaccine derived from an environmen-
tal non-tuberculous mycobacterium, Mycobacteria obuense, and
manufactured using broth culture methods. Environmental non-
tuberculous mycobacteria share multiple antigens with Mtb and
may  therefore provide cross protection, providing the rationale for
the development of this vaccine candidate.
SRL-172 is an agar-grown precursor to the DAR-901 vaccine.
Phase 1 and Phase 2 clinical trials in HIV-infected and HIV-
uninfected volunteers with SRL-172 have been conducted in the
USA, Zambia [45] and Finland [46]. The DarDar trial, a Phase 3
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efﬁcacy trial of SRL-172, was a randomized, placebo-controlled,
double-blind trial in more than 2000 HIV-infected volunteers in
Tanzania from 2001 to 2008. HIV-infected adults, with no active
TB, and with prior childhood BCG immunization and CD4+ T-cell
counts greater than 200, received either ﬁve intradermal doses of
the vaccine or an identical placebo over a 12-month period. Pri-
mary outcome measures were the prevention of disseminated and
pulmonary TB. Subjects were followed every three months for a
median of 3.3 years for evidence of TB disease. The trial was  stopped
in Year 7 by the Data and Safety Monitoring Board because the
vaccine was judged to have shown efﬁcacy in TB prevention. Def-
inite TB, deﬁned by ≥1 positive blood culture for Mtb, ≥1 positive
sputum culture(s) with ≥10 colony-forming units (CFU), ≥2 posi-
tive sputum cultures with 1–9 CFU, ≥sputum smears with ≥2 acid
fast bacilli (AFB)/100 oil immersion ﬁelds, or ≥1 positive culture, or
positive AFB smear and caseous necrosis from a sterile site (other
than blood), was statistically signiﬁcantly reduced by 39% [47].
Disseminated TB was reduced by 50% but was underpowered for
statistical signiﬁcance. Immunogenicity of the vaccine was  demon-
strated by IFN- and lymphocyte proliferative responses in PMBC
to vaccine sonicate as well as the increased presence of antibody
directed against lipoarabinomannan (LAM), a glycoprotein widely
expressed in mycobacteria [48]. No severe adverse reactions were
seen, but reactions at the vaccine site were common [47].
In 2011, in collaboration with Aeras, a high yield and scal-
able GMP  broth manufacturing process was developed from the
Master Cell Bank for SRL-172 to produce DAR-901. Following
the completion of animal toxicology and immunogenicity stud-
ies, a randomized, placebo controlled, dose escalation Phase 1
trial of DAR-901 was initiated in April 2014 in the USA with HIV-
infected and HIV-uninfected volunteers, all of whom had previously
received BCG. Immune assays will be conducted on all subjects
to compare immunogenicity of the broth-grown DAR-901 to data
from subjects who received agar-grown SRL-172 in earlier trials.
DAR-901 is intended to be a booster vaccine for the prevention of
TB in both HIV-infected and HIV-uninfected adolescents and adults
primed by childhood BCG immunization. Two Phase 3 trials in ado-
lescents and adults in TB endemic countries are in planning for
implementation upon successful completion of the ongoing Phase
1 trial: a multi-site trial in Tanzania with HIV-infected individ-
uals and a multi-site trial in India and China with HIV-uninfected
individuals.
RUTI. Dr. Pere-Joan Cardona, Unitat de Tuberculosi Experi-
mental, Universitat Autónoma de Barcelona, Badalona, Catalo-
nia, Spain
Dr. Pere-Joan Cardona described progress in the development
of RUTI, an immunotherapeutic TB vaccine being developed by
Archivel Farma, Catalonia, Spain, designed to shorten treatment
of latent TB infection (LTBI), support chemotherapy of active TB
disease and reduce recurrence rates following completion of treat-
ment. The ideal RUTI strategy would reduce 9 months of isoniazid
(INH) treatment of LTBI to only 1 month of INH combined with two
doses of RUTI.
RUTI is fragmented, Triton cleaned, liposomal Mtb  which has
been cultured under stress conditions to induce latency antigens.
The vaccine is detoxiﬁed with Triton to decrease the risk of the Koch
reaction, an exacerbated immune reaction that may  occur when
persons already infected with Mtb  are exposed to Mtb  antigens
via vaccination, and contains very low levels of the endotoxin-like
molecule, LAM. The liposomal preparation is stable at room tem-
perature and displays both adjuvant and antigen properties [49]. In
a mini-pig model of latent TB, combined INH and RUTI treatment
reduced the ratio of new to old lesions when compared to untreated
controls and INH alone [50].
A Phase 1, randomized, placebo-controlled clinical trial of RUTI
was conducted in healthy white males in Spain with no prior BCG
vaccination or history of TB infection to evaluate the tolerability
and immunogenicity of four RUTI doses between 5 g and 200 g.
Results obtained following the completion of the trial in October
2008 demonstrated that all four doses were tolerated, but higher
doses (100 g and 200 g) were accompanied by moderate pain (20
on a scale of 100) at the injection site, which was more intense after
the second inoculation. Speciﬁc immune responses against PPD and
four speciﬁc Mtb  antigens were detected 35 days after vaccination
[51].
A Phase 2 study of RUTI safety, tolerability and immunogenicity
was completed in July 2011. It was a randomized, placebo-
controlled trial in HIV-infected and HIV-uninfected patients
undergoing INH treatment for LTBI. Four weeks of INH treatment
was followed by two RUTI inoculations administered 28 days apart;
5 g, 25 g and 50 g doses of RUTI were compared to placebo.
More than ninety percent of patients experienced injection site
reaction, including erythema, induration and nodulation lasting
3–4 weeks, but self-resolved in almost all cases. The moderate local
pain was  well tolerated and had the same intensity as was observed
in the Phase 1 study. There was no evidence of a Koch reaction.
After this trial, the RUTI production process has changed to include
a ﬁltration step in an effort to reduce adverse events at the inocula-
tion site. Immune response to RUTI was  variable; frequently the TB
ELISpot IFN response for both individual TB antigens and for PPD
in the experimental samples was polyantigenic and higher than
placebo and was weaker in HIV-infected than in HIV-uninfected
subjects [52] Using a whole blood, seven-day ELISA assay for IFN
to gauge response to PPD, the 25 g RUTI dose consistently showed
an increase in IFN production versus placebo with an approx-
imately seventy-ﬁve percent response rate in both HIV-infected
and HIV-uninfected subjects [52]. Based on the Phase 2 results, the
developers designed Phase 3 clinical trials to include a single, 25 g
injection of RUTI.
Two Phase 3 clinical trials are in planning to demonstrate RUTI
efﬁcacy in reducing relapse after chemotherapy for LTBI or active
TB disease. One employs a single, 25-g injection of RUTI or a
placebo after 6 months of INH treatment for LTBI in HIV-infected
individuals where RUTI is designed to add at least 60% protection
against relapse. The second Phase 3 trial tests the relapse protec-
tion provided by a single, 25-g injection of RUTI versus placebo
three months into six months of standard chemotherapy for drug-
susceptible active TB.
BCG zmp1. Dr. Peter Sander, Institute of Medical Microbiol-
ogy, University of Zurich, Zurich, Switzerland
Despite extensive attenuation, BCG continues to retain many
of the immune evasive properties of Mtb, which may  limit its
protective efﬁcacy. Zinc metalloprotease 1 (zmp1) has been iden-
tiﬁed as one mediator of immune evasion common to both Mtb
and BCG [53,54]. The enzyme enhances bacterial survival in the
host macrophage by preventing phagosome–lysosome fusion and
inﬂammasome activation, allowing the bacteria to evade major
histocompatibility class I- or II-restricted T-cell responses [55,56].
Dr. Peter Sander presented an update on the development of a
BCG strain in which the zmp1 gene has been deleted, BCG zmp1.
The common general rationale shared by BCG zmp1, the recom-
binant BCG constructs described by Dr. Brosch, and VPM1002 is
to overcome mycobacterial immune evasion in the macrophage
phagosome, albeit by different mechanisms
Preclinical studies in mice have shown that BCG zmp1 is
more immunogenic than BCG. Despite the improved immuno-
genicity, however, there was  no statistical difference between the
zmp1 deletion mutant and wild type BCG persistence in immune
competent mice [56]. Studies of the safety of zmp1-deleted BCG
strains in SCID mice suggest that the zmp1 deletion is typically
safer than the isogenic parental strain, whether it is Danish or
Pasteur.
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BCG zmp1 has been found to be protective and safe in ani-
mal  challenge experiments conducted thus far. Low-dose challenge
studies in guinea pigs, utilizing 10–50 CFU of the virulent Mtb  strain
H37Rv administered via aerosol, demonstrated that the protective
efﬁcacy of BCG zmp1 in either the Danish or Pasteur BCG strain is
superior to standard BCG in reducing the number of tubercle bacilli
in the lung [57]. In cattle, BCG zmp1 induces stronger memory
responses than standard BCG, which has been described as the most
predictive indicator of protective efﬁcacy [58]. Challenge studies in
cattle, comparing BCG zmp1 to BCG, are in progress.
BCG PanCD (BCG Aeras Pasteur). Dr. Barry Walker, Vice
President, Preclinical Development, Aeras, Rockville, Maryland,
USA
Dr. Barry Walker discussed a vaccine strategy that combines a
non-replicating BCG with adjuvant. This strategy is intended to
develop a safer BCG vaccine for use as a booster in previously
BCG-vaccinated adolescents, adults and immune-compromised
individuals. BCG PanCD, designated BCG Aeras Pasteur, is
auxotrophic for pantothenate (Vitamin B5) and requires supple-
mentation with pantothenate for growth. Coupled with one of a
number of state-of-the-art adjuvants, the resulting vaccine could
be both safer and more effective than BCG. Studies in a mouse chal-
lenge model have shown BCG Aeras Pasteur to be as protective as
replicating BCG, while BCG adjuvanted with dimethyldioctadecy-
lammonium liposomes with monophosphoryl lipid-A (DDA/MPL)
may  be more protective than BCG alone (Walker, unpublished
results). Additional studies are underway to conﬁrm this observa-
tion.
3. Development pathways for whole mycobacteria cell TB
vaccines: BCG replacement in infants and potential for use
in adolescents and adults
Dr. Michele Tameris, University of Cape Town, South African
Tuberculosis Vaccine Initiative (SATVI), Cape Town, South Africa
Dr. Richard G. White, TB Modeling Group, Department of
Infectious Disease Epidemiology, London School of Hygiene and
Tropical Medicine, London, UK
An important issue facing developers of whole mycobacteria cell
vaccines for TB is whether to develop them primarily as possible
replacements for BCG administered to infants and young children
to prevent TB meningitis or disseminated TB, or whether to target
their development as vaccines that could contribute to efforts to
develop vaccine regimens to prevent Mtb  infection or pulmonary
TB disease in adolescents and adults. Dr. Michele Tameris began
her rationale in support of the BCG replacement strategy by noting
that, overall, BCG is known to display widely variable protection
against pulmonary TB, varying between 0 and 80%. In a 1995 meta-
analysis, BCG was found to have an overall protective effect of 74%
in newborns and infants [59]. In a recent, comprehensive meta-
analysis undertaken in an attempt to explain the wide variation
in BCG efﬁcacy, an average of 59% protection for pulmonary TB
and 85% protection against meningeal and miliary TB was seen in
infants in studies initiated between 1933 and 1988 [14]. Addition-
ally, a study of the cost effectiveness of BCG in preventing childhood
tuberculous meningitis and miliary TB demonstrated that the 100.5
million BCG vaccinations administered in 2002 were estimated to
have prevented almost 30,000 cases of tuberculous meningitis and
about 11,500 cases of miliary TB making it a highly cost-effective
intervention against severe childhood TB [11].
Despite evidence of BCG efﬁcacy in young children, however,
BCG vaccinated children continue to experience high rates of TB in
endemic areas. Additionally, BCG is not recommended for use in
HIV-infected infants due to the risk of disseminated BCG disease
[16]. More than 90% of infants in Cape Town are immunized with
BCG, yet the incidence of the spectrum of TB disease in children
under 2 years exceeded 1200 per 100,000 in the period between
July 2002 and June 2003. Prior to the development of drug therapy
for TB, the highest risk of TB mortality following primary infection
in children under 15 years of age was 12.1%, occurring in chil-
dren between the ages of 1 and 4 [60]. In addition, miliary TB and
tuberculous meningitis is concentrated in children under 3 years
of age, as found in a prospective, descriptive study conducted in
Cape Town over a 20-month period between 2003 and 2004 [61].
Dr. Tameris cited these data when calling for a better vaccine for
infants than BCG, one safe enough to use in children with HIV infec-
tion and other immunosuppressive conditions and which provides
increased protection for all forms of TB in children.
Dr. Tameris reviewed suggested approaches to reduce the risk
to infants in areas of high TB endemnicity enrolled in trials of new,
modiﬁed BCG vaccines. To minimize the risk of Mtb  infection or
TB disease, neonates will be recruited from mothers who are free
of both active and latent TB (i.e., QuantiFERON® negative). The
infants and their household contacts will be subjected to active
surveillance for symptoms of TB disease following immunization.
Stringent halting rules will be adhered to, and a rescue dose of BCG
made available if necessary at 6 months for Phase 1B trials and at
12 months for Phase 2A and 2B trials. Safety data still needs to be
generated for delayed or repeat BCG immunization in infants.
In the discussion that followed Dr. Tameris’s presentation,
workshop participants expressed concern that demonstration of
superiority of a new, modiﬁed BCG vaccine to standard BCG
would be extraordinarily difﬁcult and would require an extremely
large study population. While a new BCG vaccine that prevents
pulmonary TB in adolescents and adults would reduce Mtb  trans-
mission and therefore would eventually protect children, Dr.
Tameris emphasized that children need primary protection ded-
icated to their age group now. BCG immunization after birth is
systematic, routine and provides excellent coverage; a booster vac-
cine to enhance BCG-primed protection would keep the current
neonatal BCG immunization system intact.
Dr. Richard G. White presented a case for targeting the devel-
opment of whole mycobacterial cell vaccines for TB at adolescents
and adults to achieve the greatest epidemiological impact before
2050. He based his conclusion on the results of a modeling study
on the impact and cost-effectiveness of future TB vaccines in low-
and middle-income countries [3]. More than 80% of the 8.6 million
new cases of TB diagnosed in 2012 occurred in low- and middle-
income countries. Without an effective vaccine, modeling studies
have shown that global epidemiological goals for TB control by
2050 are unlikely to be achieved [2,4]. Dr. White and colleagues
ﬁtted variable levels of vaccine coverage, efﬁcacy and duration of
protection for different target populations into a standard TB trans-
mission model. Age, HIV status and more effective future TB control
was modeled. Impact and cost effectiveness was determined by
comparing the impact and cost of TB control with and without a
new vaccine. New vaccines were assumed to prevent active dis-
ease but not infection, to be effective in uninfected and infected
individuals, and to require two  doses. Immunization coverage was
assumed to be 82% (47–99%) for infants, 70% (42–99%) for 10-
year-old school children and 74% (68–91%) for mass vaccination
campaigns. Efﬁcacy was  varied between 40%, 60% and 80%, and
included the assumption that efﬁcacy in HIV-infected individuals
was 40% lower than in HIV-uninfected people. Duration was  var-
ied between 5 years, 10 years and lifelong protection. Finally, the
price per dose was determined through historical analysis of GAVI
prices of new vaccines and consultation with Aeras and TBVI. This
model’s results are in addition to the impact of BCG immunization
at current coverage levels.
In lower income countries, with a vaccine that provided 40%
efﬁcacy over 10 years, over the 26 years between 2024 and 2050 the
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model suggests that only about 0.6 million cases, or 2% of the total
burden, would be averted if the vaccine was targeted at infants.
In contrast, a vaccine with the same efﬁcacy and duration proﬁle
would avert 13 million cases, or 40% of the total burden, if targeted
at adolescents and adults.
A cost-effective vaccine price analysis demonstrated that a new
vaccine targeted at adolescents and adults would still be cost effec-
tive if the duration of effectiveness was as short as ﬁve years and
the efﬁcacy was as low as 20%. New vaccines with long durations
targeted at infants could only become cost-effective if the time end-
point extended beyond 2050. These results imply that new vaccines
targeted at adolescents and adults could have a large public health
impact and be cost effective, even if only short duration and low
efﬁcacy vaccines are available.
It will be critical in designing BCG replacement studies to take
into account possible non-TB-related effects of BCG, including
potential effects on all-cause mortality in the ﬁrst few months
after vaccination, potential effects on Th2 driven-conditions such
as asthma, and studies to make sure the protective effect of BCG
against leprosy is not lost [62,63].
4. Resource needs
Dr. Thomas Scriba, University of Cape Town, South African
Tuberculosis Vaccine Initiative (SATVI), Cape Town, South Africa
Dr. David Hokey, Senior Director of Immunology and Animal
Studies, Aeras, Rockville, Maryland, USA
As TB vaccines candidates enter clinical trials, common and stan-
dardized assays for immunogenicity and efﬁcacy are needed to
permit a rational selection of the most promising candidates to
advance into later-stage efﬁcacy trials [64]. Assay development
has been limited by both the lack of a human challenge model
for TB and an incomplete understanding of the immune correlates
of protection. Dr. Thomas Scriba began his presentation on the
selection of immune assays for whole mycobacteria cell vaccine
candidates by noting that recent advances in our understanding
of protective immunity to TB reveal a complex interplay between
many cell types of both the innate and adaptive immune systems
[65]. Whole mycobacteria cell vaccines provide a broad spectrum
of antigens, including lipid and phospho-antigens in addition to
protein antigens, and generally induce better immunological mem-
ory than subunit vaccines, potentially increasing the complexity
of assays required to fully evaluate resultant immunogenicity. The
non-speciﬁc protection against infection and mortality that whole
mycobacteria cell vaccines may  provide may  further increase the
challenges in developing appropriate assays to assess the full scope
of the effects of these vaccines [66,67].
Assays should identify the immune cells that respond to the
speciﬁc antigenic challenges provided by these vaccines, and
demonstrate the memory state of the cells and the functional con-
sequence of the response. The BCG-associated CD4+ T-cell response
peaks 6–10 weeks after vaccination in BCG naïve infants [68],
but older populations display a much more variable response
depending on their exposure history to BCG, TB and environmental
mycobacteria. Potential attributes of the response to follow include
the de novo proliferative responses of BCG-speciﬁc CD4+ T-cells in
infants, de novo CD4+ T-cell expression of cytotoxic responses in
infants, and increases in populations of conventional CD8+ T-cells,
as well as the more unconventional  T-cells, CD3-CD56hi NK cells,
CD3-CD56int NK cells, and CD3+CD56+ NKT-cells. Mycobacterial
growth inhibition assays (MGIAs) may  measure a unique functional
immunity that most accurately assesses vaccine-induced protec-
tion [69].
Dr. Scriba concluded his presentation by saying that assays
should capture the breadth of the immune cells and effector
functions induced by the vaccine. He cautioned that commonly
used assays, such as soluble cytokine release assays and the
ELISpot assay, may  be too simple and univariate to provide
sufﬁcient information. Assays potentially capable of capturing
relevant complexity include intracellular cytokine/cytotoxic stain-
ing and proliferation assays visualized through ﬂow cytometry,
and tetramer assays to capture the antigenic complexity of CD4+
T-cells, CD8+ T-cells, as well as CD1- and MR1-restricted T-cells.
MGIAs may  be the best overall measure of effector function. Vari-
ations in results due to the use of fresh or cryopreserved cells,
whole blood, or peripheral blood mononuclear cells continue to be
determined. Antibody responses may  also be a valuable indicator
of protective immunity but are as yet undeﬁned. More predictive
assays for protective immunity against TB will require future stud-
ies that address the still incompletely understood immunological
mechanisms involved in response to Mtb  infection and TB vaccine
candidate administration.
Dr. David Hokey discussed the reagents needed to differenti-
ate and compare whole mycobacteria cell TB vaccine candidates.
Many challenges confront TB vaccine development, including the
dearth of understanding as to the actual components of a protective
human immune response to Mtb  infection and TB disease. Animal
challenge studies can be long and expensive and the correlation
between pre-clinical studies in animal models and human protec-
tion is uncertain. Assays may  need to be designed to assess the
speciﬁc advantages of these candidates over BCG, such as the abil-
ity to induce greater CD8+ T-cell responses, a greater shift toward
Th1 cytokine production, and recognition of new antigenic epitopes
induced by non-tuberculous mycobacteria. Despite these chal-
lenges, some progress has been made in identifying the required
immune responses for TB control. These include identiﬁcation of
the critical role in TB control played by CD4+ and CD8+ T-cells, IFN-
 pathways and TNF. Work continues on the reﬁnement of animal
models, the expansion of immune assays to report on the immune
response with greater complexity, and the growth of the clinical
pipeline of new TB vaccines. Unfortunately, no clear correlate has
been identiﬁed for the positive, non-speciﬁc effects of BCG, with
the exception of one epigenetic marker [70].
The global clinical pipeline of sixteen TB vaccine candidates
includes ﬁve whole mycobacteria cell vaccines, four which were
presented at this meeting (three of the seven whole cell vaccines
discussed in Session 1 are in the preclinical stage of development).
The potential advantages of whole mycobacteria cell vaccines
have been emphasized throughout this meeting, and include their
broader antigen coverage, the natural adjuvanting properties of
these cells, and their ease of manufacture. Disadvantages include
the concern that since development of active TB may not provide
immune protection against future infections, whole mycobacteria
cell vaccine responses may  not be able to provide protection against
Mtb infection or TB disease.
A major challenge to conducting trials of whole mycobacte-
ria cell vaccines is the need to accurately identify vaccine strains
from naturally occurring Mtb  as well as from environmental
non-tuberculous mycobacteria, ubiquitous, soil-based organisms
particularly common in tropical and subtropical regions. It will
be critically important to develop accurate, standardized assays
capable of easily and quickly distinguishing between mycobac-
terial species. Additionally, for adolescents and adults living in
tropical and subtropical regions in particular, continual exposure
to non-tuberculous environmental mycobacteria makes distin-
guishing vaccine responses from responses to other mycobacteria
difﬁcult [13].
Most immune assays for measuring responses to vaccines,
whether simple assays measuring a single variable, or with
more complex outcomes, require antigen for in vitro stimula-
tion. Standardized reagents from a common source would allow
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comparability between clinical trials. Possible antigen sources
include the vaccine itself; PPD, protein antigens or peptides; or Mtb
lysate.
Research resource needs were identiﬁed in several areas:
expanding current assays beyond the Th1 response to improve
measurements of immunity; using systems biology to identify
correlates of protection; and developing further disease models,
including an animal transmission model and a human challenge
model.
5. Summary panel discussion
Panel members:
Dr. Barry Bloom Harvard University Distinguished Service Pro-
fessor and Joan L. and Julius H. Jacobson Professor of Public
Health, Department of Immunology and Infectious Diseases,
Department of Global Health and Population, Harvard School
of Public Health, Boston, MA,  USA.
Dr. Hazel Dockrell, Professor of Immunology, London School of
Hygiene and Tropical Medicine, London, UK.
Dr. Bernard Fritzell, Tuberculosis Vaccine Initiative (TBVI),
Lelystad, the Netherlands.
Dr. Willem Hanekom, Tuberculosis/Global Health, Bill and
Melinda Gates Foundation, Seattle, Washington, USA.
Dr. Stefan H.E. Kaufmann, Managing Director, Max  Planck Insti-
tute for Infection Biology and Professor of Immunology and
Microbiology, Charité Clinics, Berlin, Germany.
Dr. Michael Levin, Director, Wellcome Center for Clinical Trop-
ical Medicine, Imperial College, London, UK.
Dr. January Weiner, Department of Immunology, Max  Planck
Institute for Infection Biology, Berlin, Germany.
In the concluding panel discussion, Dr. Hazel Dockrell empha-
sized the importance of developing at least one validated assay,
using a standardized protocol, equipment and reagents, to be used
in all clinical TB vaccine trials, especially in multi-center trials of a
single vaccine. Clinical studies of whole mycobacteria cell vaccines
should undertake a broad and complex analysis of the immune
response, utilizing a variety of assays performed in as standard-
ized a way as possible. Systems biology investigations represent
powerful new strategies to identify possible immune correlates of
protection [6]. Systems biology utilizes gene expression methods to
identify a signature of immune response-associated gene activity
accompanying certain clinically identiﬁable events, such as a tran-
sition from latent Mtb  infection to active TB disease. Dr. Dockrell
noted that it may  be easier to identify biosignatures indicative of
early clinical disease than those associated with protection from
disease. In addition, systems biology whole blood studies primar-
ily assess immune responses occurring within the vascular space
rather than in the pulmonary parenchyma, the actual site of Mtb
infection and most TB disease.
In light of the number of vaccine candidates to be developed and
the enormous expense of clinical efﬁcacy trials, Dr. Barry Bloom
emphasized the urgent need for innovative strategies to measure
effectiveness prior to committing to large scale vaccine trials. Sys-
tems biology approaches to ﬁnding gene expression signatures
offer hope for predicting risk for progression to disease and possi-
bly deﬁning biomarkers of protection. Noting several fundamental
differences in responses between humans and experimental ani-
mals to Mtb  and citing the success of live challenge strategies that
have been valuable for evaluating vaccines for malaria and enteric
diseases, Dr. Bloom urged serious attention be given to the develop-
ment of auxotrophic or conditional promotor-regulated Mtb  strains
that could be used as safe, live TB challenges in humans that would
establish the ability of vaccine candidates to induce Mtb  killing.
Dr. Stefan H.E. Kaufmann concluded the presentations by not-
ing that the development of many whole mycobacteria cell TB
vaccines are advancing, yet a great amount of work remains to
be done in assessing the ultimate value of this vaccination strat-
egy. While BCG replacement in infants has value it will not be
easy to accomplish given the challenges inherent in comparing a
new vaccine with an existing, safe product known to provide the
only established efﬁcacy against TB disease. Opportunities should
be sought to diversify the use of whole mycobacteria cell TB vac-
cines in preventing infection and disease in adolescents and adults.
Moreover, different vaccination schedules should be explored such
as whole-cell vaccination alone or as a prime followed by a boost
with a different platform, for example, vector-delivered vaccines
or protein–adjuvant combinations. Similarly, different delivery
modalities should be explored such as aerosol delivery in addition
to intramuscular or intradermal application. Utilization of adap-
tive trial designs, allowing efﬁcient modiﬁcation of the clinical
trials according to new data arising, should be considered. Addi-
tionally, samples from ongoing clinical studies should be collected
and stored to gain deeper insights into the host response evoked by
the vaccine undergoing clinical testing and to provide information
to guide future vaccine design. Until and unless speciﬁc antigens
are identiﬁed that prompt a protective immune response to Mtb,
whole mycobacteria cell vaccines will continue to provide a criti-
cally important strategy in efforts to develop a vaccine against the
global public health scourge of TB. To Dr. Kaufmann, success of a
full development of an efﬁcacious and safe TB vaccine will only be
possible if all stakeholders share their knowledge and wisdom and
work together as closely as possible.
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